4-Antibody appoints ceo and new board member

To develop more partnerships with corporate pharma

Swiss antibody specialist 4-Antibody has appointed Robert Burns as chief executive and Thomas von Rüden to its board of directors.

Burns has previously held senior positions in the antibody area as ceo of Oslo, Norway-based Affitech and Celldex Therapeutics in the US.

Max Burger, 4-Antibody’s chairman, said Burns is a deal-maker and has the experience to drive 4-Antibody forward to achieve additional multi-target collaborations with corporate pharma to add to the partnership recently put in place with Boehringer Ingelheim.

Von Rüden was formerly ceo at Direvo Industrial Biotechnology in Cologne, Germany. Prior to this, he was chairman of Direvo’s Advisory Board and worked as president and ceo at Direvo Biotech until Bayer Schering acquired the company in September 2008.

Von Rüden also spent six years as cso and executive VP of Business Development with MorphoSys in Munich. Before that he was director of Molecular Biology responsible for drug discovery in oncology at Boehringer Ingelheim in Vienna.

‘We expect Thomas’s knowledge of key trends in pharma antibody discovery and development to add incremental momentum to our pursuit of new corporate partnerships as well as our internal drug discovery and development programmes,’ said Burns.

You may also like

Ingredients

4-Antibody to collaborate with HGS

To discover and develop fully human therapeutic antibodies
Research & Development

4-Antibody to collaborate with Boehringer Ingelheim

Long-term collaboration for targets in various disease indications
Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Subscribe now